PCA
CPRX

Private Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Private Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-826,500
Closed -$2.46M – 113
2014
Q4 		$2.46M Buy
+826,500
New +$2.27M 0.92% 50

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return

Private Capital Advisors's CPRX Position: Q1 2015 in Review

Private Capital Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q1 2015, closing a stake of 826,500 shares — an estimated $2.46M sold.

Private Capital Advisors first reported a position in CPRX in Q4 2014 and held it in 1 quarter. The position peaked at $2.46M in Q4 2014. 66 funds tracked by Wall St. Rank hold CPRX as of Q1 2015.

  • Private Capital Advisors reported no remaining Catalyst Pharmaceutical position as of Q1 2015 after selling out during the quarter.
  • Private Capital Advisors sold 826,500 Catalyst Pharmaceutical shares in Q1 2015, an estimated $2.46M.
  • Private Capital Advisors first reported a position in Catalyst Pharmaceutical in Q4 2014 and held it in 1 quarter.
  • Private Capital Advisors's Catalyst Pharmaceutical position peaked at $2.46M in Q4 2014.
  • 66 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2015.

Based on Private Capital Advisors's 13F filing for Q1 2015, filed 23 Apr 2015.